180 related articles for article (PubMed ID: 2869661)
1. Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
Ulbricht A; Färber I; Wutzler P
Acta Virol; 1985 Dec; 29(6):493-8. PubMed ID: 2869661
[TBL] [Abstract][Full Text] [Related]
2. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Ahlmén J; Wijnween AC; Brynger H; Lycke E
Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
Chatis PA; Miller CH; Schrager LE; Crumpacker CS
N Engl J Med; 1989 Feb; 320(5):297-300. PubMed ID: 2536137
[No Abstract] [Full Text] [Related]
4. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous herpes simplex virus infections.
Arbesfeld DM; Thomas I
Am Fam Physician; 1991 May; 43(5):1655-64. PubMed ID: 1826983
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.
Lawee D; Rosenthal D; Aoki FY; Portnoy J
CMAJ; 1988 Feb; 138(4):329-33. PubMed ID: 2962712
[TBL] [Abstract][Full Text] [Related]
7. Effect of trisodium phosphonoformate and idoxuridine on experimental herpes simplex keratitis in immunized and non-immunized rabbits.
Alenius S; Laurent U; Oberg B
Acta Ophthalmol (Copenh); 1980 Apr; 58(2):167-73. PubMed ID: 6249066
[TBL] [Abstract][Full Text] [Related]
8. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Erlich KS; Jacobson MA; Koehler JE; Follansbee SE; Drennan DP; Gooze L; Safrin S; Mills J
Ann Intern Med; 1989 May; 110(9):710-3. PubMed ID: 2522751
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir.
Al-Samarai A; Kinghorn G; Potter C
Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616
[No Abstract] [Full Text] [Related]
10. A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice.
Kern ER; Richards JT; Overall JC; Glasgow LA
Antiviral Res; 1981 Nov; 1(4):225-35. PubMed ID: 6280607
[TBL] [Abstract][Full Text] [Related]
11. Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.
MacPhail LA; Greenspan D; Schiødt M; Drennan DP; Mills J
Oral Surg Oral Med Oral Pathol; 1989 Apr; 67(4):427-32. PubMed ID: 2524706
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of antiherpetic drugs in animal experiments.
Streissle G
Adv Ophthalmol; 1979; 38():43-8. PubMed ID: 525527
[No Abstract] [Full Text] [Related]
13. The potential of phosphonoformate for the treatment of herpex simplex labialis.
Oxford J
J Antimicrob Chemother; 1980 Nov; 6(6):694-5. PubMed ID: 6449499
[No Abstract] [Full Text] [Related]
14. Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet.
Hedin G; Weiland O; Ljunggren K; Strömberg A; Nordenfelt E; Hansson BG; Oberg B
Prog Clin Biol Res; 1987; 234():309-20. PubMed ID: 2957702
[No Abstract] [Full Text] [Related]
15. Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs.
Mayo DR; Lucia HL; Hsiung GD
Intervirology; 1983; 19(1):26-32. PubMed ID: 6298142
[TBL] [Abstract][Full Text] [Related]
16. Disseminating herpes simplex infection: primary lesions in urinary bladder and successful treatment with forscarnet sodium.
Blohmé I; Ahlmén J; Jeansson S; Ranch T; Brynger H
Transplant Proc; 1984 Dec; 16(6):1672-4. PubMed ID: 6239431
[No Abstract] [Full Text] [Related]
17. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
Oberg B
Pharmacol Ther; 1989; 40(2):213-85. PubMed ID: 2543994
[TBL] [Abstract][Full Text] [Related]
18. The effects of topical foscarnet in a new model of herpes simplex skin infection.
van Genderen J; Wolthuis OL; Ariens AT; Ericson AC; Datema R
J Antimicrob Chemother; 1987 Oct; 20(4):547-56. PubMed ID: 2960644
[TBL] [Abstract][Full Text] [Related]
19. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
Barton SE; Munday PE; Kinghorn GR; van der Meijden WI; Stolz E; Notowicz A; Rashid S; Schuller JL; Essex-Cater AJ; Kuijpers MH
Genitourin Med; 1986 Aug; 62(4):247-50. PubMed ID: 2942457
[TBL] [Abstract][Full Text] [Related]
20. Foscarnet effective in acyclovir-resistant herpes.
Am Pharm; 1991 Nov; NS31(11):12. PubMed ID: 1836936
[No Abstract] [Full Text] [Related]
[Next] [New Search]
